Sugi Predict

Sugi Predict / Compounds / SCHEMBL1979776

SCHEMBL1979776

SCHEMBL1979776

CC[C@H]1NC(=O)N(c2ccc(Oc3ccc(C#N)c(OCC4CC4)c3)nc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 2/20 0.41
▸ XDH P47989 3/20 0.35
▸ TBK1 Q9UHD2 2/20 0.34
▸ IKBKE Q14164 1/20 0.34
▸ ACACB O00763 3/20 0.33
▸ HRH3 Q9Y5N1 2/20 0.33
▸ AR P10275 1/20 0.33
▸ ABL1 P00519 1/20 0.32
▸ SRC P12931 1/20 0.32
▸ ABL2 P42684 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ ACACA Q13085 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939598 1.00 GPR119 (0.41) GPR119XDHTBK1IKBKEACACB
SCHEMBL18952981 0.90 BCAT2 (0.33) GPR119AR
SCHEMBL1979013 0.89 AR (0.40) GPR119AR
SCHEMBL13832584 0.88 GPR119 (0.35) GPR119ACACBHRH3CYP3A4CYP2C9
SCHEMBL1980154 0.87 IRAK4 (0.36) GPR119XDHAR
SCHEMBL1980470 0.87 SLC22A12 (0.36) GPR119HRH3
SCHEMBL30939607 0.87 SLC22A12 (0.36) GPR119HRH3
SCHEMBL1981120 0.86 CHRM2 (0.34) GPR119AR
SCHEMBL13828719 0.86 NPSR1 (0.36) GPR119HRH3AR
SCHEMBL29384188 0.83 ALDH1A1 (0.37) GPR119HRH3AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US claimed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 — — US claimed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 — — US claimed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 — — US claimed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 — — US claimed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 — — US claimed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 — — EP claimed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 — — US claimed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US claimed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US claimed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP claimed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 — — US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 — — CN disclosed
CN-108472288-B Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-05-28 — — CN disclosed
US-11944623-B2 Modulators of Kv3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2024-04-02 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 GPR119 1915/4885XDH 3104/4885TBK1 2640/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 GPR119 1915/4885XDH 3104/4885TBK1 2640/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 GPR119 1915/4885XDH 3104/4885TBK1 2640/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 GPR119 1915/4885XDH 3104/4885TBK1 2640/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 GPR119 1915/4885XDH 3104/4885TBK1 2640/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 GPR119 1915/4885XDH 3104/4885TBK1 2640/4885
US-11944623-B2 Modulators of Kv3 channels to treat pain KCNN3, KCNA3, KCND3 GPR119 2001/4885XDH 3115/4885TBK1 1051/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 GPR119 1997/4885XDH 3302/4885TBK1 2900/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 GPR119 2001/4885XDH 3115/4885TBK1 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.